Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 141

1.

Efficacy and safety of TAK-085 compared with eicosapentaenoic acid in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the omega-3 fatty acids randomized double-blind (ORD) study.

Tatsuno I, Saito Y, Kudou K, Ootake J.

J Clin Lipidol. 2013 May-Jun;7(3):199-207. doi: 10.1016/j.jacl.2013.01.006. Epub 2013 Feb 4.

PMID:
23725919
[PubMed - indexed for MEDLINE]
2.

Long-term safety and efficacy of TAK-085 in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the omega-3 fatty acids randomized long-term (ORL) study.

Tatsuno I, Saito Y, Kudou K, Ootake J.

J Clin Lipidol. 2013 Nov-Dec;7(6):615-25. doi: 10.1016/j.jacl.2013.09.002. Epub 2013 Sep 18.

PMID:
24314359
[PubMed - indexed for MEDLINE]
3.

Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial).

Bays HE, Ballantyne CM, Kastelein JJ, Isaacsohn JL, Braeckman RA, Soni PN.

Am J Cardiol. 2011 Sep 1;108(5):682-90. doi: 10.1016/j.amjcard.2011.04.015. Epub 2011 Jun 16.

PMID:
21683321
[PubMed - indexed for MEDLINE]
4.

The triglyceride-lowering effects of a modest dose of docosahexaenoic acid alone versus in combination with low dose eicosapentaenoic acid in patients with coronary artery disease and elevated triglycerides.

Schwellenbach LJ, Olson KL, McConnell KJ, Stolcpart RS, Nash JD, Merenich JA; Clinical Pharmacy Cardiac Risk Service Study Group.

J Am Coll Nutr. 2006 Dec;25(6):480-5.

PMID:
17229894
[PubMed - indexed for MEDLINE]
5.

A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial).

Maki KC, Orloff DG, Nicholls SJ, Dunbar RL, Roth EM, Curcio D, Johnson J, Kling D, Davidson MH.

Clin Ther. 2013 Sep;35(9):1400-11.e1-3. doi: 10.1016/j.clinthera.2013.07.420. Epub 2013 Aug 30.

PMID:
23998969
[PubMed - indexed for MEDLINE]
6.

Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).

Ballantyne CM, Bays HE, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA, Soni PN.

Am J Cardiol. 2012 Oct 1;110(7):984-92. doi: 10.1016/j.amjcard.2012.05.031. Epub 2012 Jul 20.

PMID:
22819432
[PubMed - indexed for MEDLINE]
7.

Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia.

McKenney JM, Sica D.

Pharmacotherapy. 2007 May;27(5):715-28. Review.

PMID:
17461707
[PubMed - indexed for MEDLINE]
8.

The effect of a 12-week course of omega-3 polyunsaturated fatty acids on lipid parameters in hypertriglyceridemic adult HIV-infected patients undergoing HAART: a randomized, placebo-controlled pilot trial.

Peters BS, Wierzbicki AS, Moyle G, Nair D, Brockmeyer N.

Clin Ther. 2012 Jan;34(1):67-76. doi: 10.1016/j.clinthera.2011.12.001. Epub 2011 Dec 31.

PMID:
22212377
[PubMed - indexed for MEDLINE]
9.

Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.

Davidson MH, Stein EA, Bays HE, Maki KC, Doyle RT, Shalwitz RA, Ballantyne CM, Ginsberg HN; COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators.

Clin Ther. 2007 Jul;29(7):1354-67.

PMID:
17825687
[PubMed - indexed for MEDLINE]
10.

A new pure ω-3 eicosapentaenoic acid ethyl ester (AMR101) for the management of hypertriglyceridemia: the MARINE trial.

Jacobson TA.

Expert Rev Cardiovasc Ther. 2012 Jun;10(6):687-95. doi: 10.1586/erc.12.56.

PMID:
22894624
[PubMed - indexed for MEDLINE]
11.

Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial.

Kastelein JJ, Maki KC, Susekov A, Ezhov M, Nordestgaard BG, Machielse BN, Kling D, Davidson MH.

J Clin Lipidol. 2014 Jan-Feb;8(1):94-106. doi: 10.1016/j.jacl.2013.10.003. Epub 2013 Oct 14.

PMID:
24528690
[PubMed - indexed for MEDLINE]
12.

Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARINE study).

Braeckman RA, Manku MS, Bays HE, Stirtan WG, Soni PN.

Prostaglandins Leukot Essent Fatty Acids. 2013 Sep;89(4):195-201. doi: 10.1016/j.plefa.2013.07.005. Epub 2013 Aug 1.

PMID:
23992935
[PubMed - indexed for MEDLINE]
13.

Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study).

Bays HE, Braeckman RA, Ballantyne CM, Kastelein JJ, Otvos JD, Stirtan WG, Soni PN.

J Clin Lipidol. 2012 Nov-Dec;6(6):565-72. doi: 10.1016/j.jacl.2012.07.001. Epub 2012 Jul 24.

PMID:
23312052
[PubMed - indexed for MEDLINE]
14.

Prescription omega-3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic subjects.

Roth EM, Bays HE, Forker AD, Maki KC, Carter R, Doyle RT, Stein EA.

J Cardiovasc Pharmacol. 2009 Sep;54(3):196-203. doi: 10.1097/FJC.0b013e3181b0cf71.

PMID:
19597368
[PubMed - indexed for MEDLINE]
15.

Prescription n-3 fatty acids, but not eicosapentaenoic acid alone, improve reference memory-related learning ability by increasing brain-derived neurotrophic factor levels in SHR.Cg-Lepr(cp)/NDmcr rats, a metabolic syndrome model.

Hashimoto M, Inoue T, Katakura M, Tanabe Y, Hossain S, Tsuchikura S, Shido O.

Neurochem Res. 2013 Oct;38(10):2124-35. doi: 10.1007/s11064-013-1121-1. Epub 2013 Aug 21.

PMID:
23963508
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Omega-3 fatty acid concentrates in the treatment of moderate hypertriglyceridemia.

Skulas-Ray AC, West SG, Davidson MH, Kris-Etherton PM.

Expert Opin Pharmacother. 2008 May;9(7):1237-48. doi: 10.1517/14656566.9.7.1237. Review.

PMID:
18422480
[PubMed - indexed for MEDLINE]
17.

Differentiating prescription omega-3-acid ethyl esters (P-OM3) from dietary-supplement omega-3 fatty acids.

Brunton S, Collins N.

Curr Med Res Opin. 2007 May;23(5):1139-45. Review. Erratum in: Curr Med Res Opin. 2008 Jan;24(1):247.

PMID:
17519081
[PubMed - indexed for MEDLINE]
18.

Early impact of prescription Omega-3 fatty acids on platelet biomarkers in patients with coronary artery disease and hypertriglyceridemia.

Serebruany VL, Miller M, Pokov AN, Lynch D, Jensen JK, Hallén J, Atar D.

Cardiology. 2011;118(3):187-94. doi: 10.1159/000329300. Epub 2011 Jun 22.

PMID:
21701167
[PubMed - indexed for MEDLINE]
19.

Prescription omega-3-acid ethyl esters for the treatment of very high triglycerides.

Sadovsky R, Kris-Etherton P.

Postgrad Med. 2009 Jul;121(4):145-53. doi: 10.3810/pgm.2009.07.2020. Review.

PMID:
19641280
[PubMed - indexed for MEDLINE]
20.

n-3 fatty acids and cardiovascular events after myocardial infarction.

Kromhout D, Giltay EJ, Geleijnse JM; Alpha Omega Trial Group.

N Engl J Med. 2010 Nov 18;363(21):2015-26. doi: 10.1056/NEJMoa1003603. Epub 2010 Aug 28.

PMID:
20929341
[PubMed - indexed for MEDLINE]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk